Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 3/20 | 0.41 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054280 | 0.86 | ESR1 (0.38) | LMNAESR1KDM4EKMT2ABRD4 | |
| SCHEMBL14533496 | 0.83 | ESR1 (0.36) | LMNAESR1KDM4EBRD4 | |
| SCHEMBL11287985 | 0.83 | TRPM5 (0.42) | TRPM5TRPM4OPRK1LMNAPDE3A | |
| SCHEMBL11284457 | 0.83 | TRPM5 (0.42) | TRPM5TRPM4OPRK1LMNAPDE3A | |
| SCHEMBL11281221 | 0.83 | TRPM5 (0.42) | TRPM5TRPM4OPRK1LMNAPDE3A | |
| SCHEMBL11761364 | 0.79 | ATM (0.41) | TRPM5TRPM4OPRK1LMNAPDE3A | |
| SCHEMBL1623970 | 0.75 | ATM (0.46) | TRPM5TRPM4LMNAATMMEN1 | |
| SCHEMBL6510724 | 0.74 | OPRK1 (0.46) | TRPM5TRPM4OPRK1LMNAPDE3A | |
| SCHEMBL9530954 | 0.74 | ALDH1A1 (0.36) | TRPM5TRPM4OPRK1LMNAPDE3A | |
| SCHEMBL12197335 | 0.71 | GSK3B (0.39) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
| US-8088759-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088759-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | TRPM5 638/4885TRPM4 1023/4885OPRK1 99/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | TRPM5 3628/4885TRPM4 3920/4885OPRK1 4655/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | TRPM5 638/4885TRPM4 1023/4885OPRK1 99/4885 |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | TRPM5 638/4885TRPM4 1023/4885OPRK1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.